BioMérieux


bioMérieux is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.
bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris stock exchange.

Revenue

bioMérieux had revenues of €2.7 billion as of 2019 with 90% of sales occurring outside France.

History

In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux. In 1963 Alain Mérieux founded BD Mérieux, of which he assumed total control in 1973. BD Mérieux would later become bioMérieux. The company expanded its services and offerings through product development, acquisitions and partnerships:
Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Belingard is President, and Alexandre Mérieux is General Director. *bioMérieux is listed on the stock exchange in 2004.

Shareholders

List in 2019.
Nom
Merieux Alliance58,9%
Famille Dassault5,10%
Jupiter Asset Management4,62%
Sofina2,12%
Oddo Bhf Asset Management1,68%
Capital Research & Management1,33%
Norges Bank Investment Management1,29%
The Vanguard Group0,95%
BlackRock Fund Advisors0,62%
Candriam Belgium0,61%